Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK, and PD of ALN-F1202 in Healthy Adults
NCT06669234Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2025
- Primary completion
- Jul 2026
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in thromboembolic disease and hereditary angioedema (HAE) comparing ALN-F1202 with Placebo (2 arms). Primary endpoints: Incidence of Treatment Emergent Adverse Events up to 190 Days and Severity of Treatment Emergent Adverse Events up to 190 Days. Started Mar 2025; status: completed.
02
Drugs
ALN-F1202
03
Conditions
thromboembolic diseasehereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT06669234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06669234.